Loading...
Stem Cell Authority, Ltd.
SCAL•PNK
Healthcare
Medical - Care Facilities
$0.00
$0.00(0.00%)

Over the past four quarters, Stem Cell Authority, Ltd. demonstrated steady revenue growth, increasing from $0.00 in Q2 2023 to $0.00 in Q4 2023. Operating income reached -$510.00 in Q4 2023, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$507.00, reflecting operational efficiency. Net income rose to -$507.00, with EPS at $0.00. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan